- Home
- GYRE vs AXG Comparison
GYRE vs AXG Comparison
Compare GYRE & AXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- AXG
- Stock Information
- Founded
- GYRE 2002
- AXG 2021
- Country
- GYRE United States
- AXG Hong Kong
- Employees
- GYRE N/A
- AXG N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- AXG Investment Bankers/Brokers/Service
- Sector
- GYRE Health Care
- AXG Finance
- Exchange
- GYRE Nasdaq
- AXG Nasdaq
- Market Cap
- GYRE 755.7M
- AXG 692.6M
- IPO Year
- GYRE N/A
- AXG 2023
- Fundamental
- Price
- GYRE $8.19
- AXG $3.59
- Analyst Decision
- GYRE Strong Buy
- AXG
- Analyst Count
- GYRE 2
- AXG 0
- Target Price
- GYRE $17.00
- AXG N/A
- AVG Volume (30 Days)
- GYRE 60.0K
- AXG 966.7K
- Earning Date
- GYRE 11-07-2025
- AXG 06-30-2025
- Dividend Yield
- GYRE N/A
- AXG N/A
- EPS Growth
- GYRE N/A
- AXG N/A
- EPS
- GYRE 0.04
- AXG N/A
- Revenue
- GYRE $107,265,000.00
- AXG $3,316,000.00
- Revenue This Year
- GYRE $15.25
- AXG $28.53
- Revenue Next Year
- GYRE $33.14
- AXG $54.60
- P/E Ratio
- GYRE $211.54
- AXG N/A
- Revenue Growth
- GYRE 2.13
- AXG N/A
- 52 Week Low
- GYRE $6.11
- AXG $2.91
- 52 Week High
- GYRE $19.00
- AXG $4.17
- Technical
- Relative Strength Index (RSI)
- GYRE 59.01
- AXG N/A
- Support Level
- GYRE $7.12
- AXG N/A
- Resistance Level
- GYRE $7.42
- AXG N/A
- Average True Range (ATR)
- GYRE 0.34
- AXG 0.00
- MACD
- GYRE 0.04
- AXG 0.00
- Stochastic Oscillator
- GYRE 94.82
- AXG 0.00
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About AXG Solowin Holdings Class A Ordinary Share
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.